Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Profound Medical Corp (PROF)

Profound Medical Corp (PROF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 222,773
  • Shares Outstanding, K 30,227
  • Annual Sales, $ 10,680 K
  • Annual Income, $ -27,820 K
  • EBIT $ -43 M
  • EBITDA $ -42 M
  • 60-Month Beta 0.57
  • Price/Sales 21.26
  • Price/Cash Flow N/A
  • Price/Book 7.05

Options Overview Details

View History
  • Implied Volatility 84.29% (-28.19%)
  • Historical Volatility 58.58%
  • IV Percentile 41%
  • IV Rank 19.06%
  • IV High 262.22% on 12/02/25
  • IV Low 42.39% on 05/19/25
  • Expected Move (DTE 19) 0.37 (5.07%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 17
  • Volume Avg (30-Day) 45
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 1,201
  • Open Int (30-Day) 1,067
  • Expected Range 7.00 to 7.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.28
  • Number of Estimates 2
  • High Estimate -0.25
  • Low Estimate -0.30
  • Prior Year -0.20
  • Growth Rate Est. (year over year) -40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.09 +21.02%
on 12/02/25
7.95 -7.30%
on 12/18/25
+0.91 (+14.09%)
since 11/26/25
3-Month
4.86 +51.65%
on 10/01/25
7.95 -7.30%
on 12/18/25
+2.15 (+41.19%)
since 09/26/25
52-Week
3.76 +96.01%
on 09/10/25
7.99 -7.76%
on 01/02/25
+0.32 (+4.54%)
since 12/26/24

Most Recent Stories

More News
Profound Medical Corp. Announces Upsize of Private Placement

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has increased the size of its private placement...

PRN.TO : 10.25 (+2.09%)
PROF : 7.37 (-1.86%)
Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th

TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the closing of its previously announced registered direct...

PRN.TO : 10.25 (+2.09%)
PROF : 7.37 (-1.86%)
Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement

TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (Nasdaq:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the sale of 5,142,857 common shares at a purchase price...

PRN.TO : 10.25 (+2.09%)
PROF : 7.37 (-1.86%)
Stanford Medicine’s Dr. Pejman Ghanouni Receives RSNA’s Cum Laude Award for CAPTAIN Perioperative Data Presentation

TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

PRN.TO : 10.25 (+2.09%)
PROF : 7.37 (-1.86%)
Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings

TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

PRN.TO : 10.25 (+2.09%)
PROF : 7.37 (-1.86%)
Profound Medical Celebrates The Hong Center’s 200th Independent TULSA Procedure for Prostate Disease

TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

PRN.TO : 10.25 (+2.09%)
PROF : 7.37 (-1.86%)
Profound Medical Reports Strong Third Quarter 2025 Financial Results

TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered,...

PRN.TO : 10.25 (+2.09%)
PROF : 7.37 (-1.86%)
Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand

TORONTO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered,...

PRN.TO : 10.25 (+2.09%)
PROF : 7.37 (-1.86%)
Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia

Agreement creates runway for Profound’s incision-free and radiation-free therapies for the ablation of diseased tissue, to penetrate the largest healthcare market in the Middle East All required...

PRN.TO : 10.25 (+2.09%)
PROF : 7.37 (-1.86%)
Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight

TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

PRN.TO : 10.25 (+2.09%)
PROF : 7.37 (-1.86%)

Business Summary

Profound Medical Corp. is a medical technology company. It is focused on a therapeutics platform which provides the precision of real-time Magnetic Resonance Imaging technology for the incision-free ablation of diseased tissue. The company principally commercialized the TULSA-PRO(R) and Sonalleve(R)...

See More

Key Turning Points

3rd Resistance Point 7.69
2nd Resistance Point 7.60
1st Resistance Point 7.48
Last Price 7.37
1st Support Level 7.27
2nd Support Level 7.18
3rd Support Level 7.06

See More

52-Week High 7.99
Last Price 7.37
Fibonacci 61.8% 6.37
Fibonacci 50% 5.88
Fibonacci 38.2% 5.38
52-Week Low 3.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar